Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

<div>Kaplan–Meier plot of pancreas and kidney allograft survival. (a) Pancreas allograft failure. (b) Pancreas allograft failure according to transplant order. (c) Kidney allograft failure among those who received SPK only. EAE: extended alemtuzumab exposure; PAK: pancreas after kidney; PTA: pancreas transplant alone; SIM: standard induction and maintenance therapy; SPK: simultaneous pancreas and kidney.</div>

Canadian Journal of Infectious Diseases and Medical Microbiology

fig3

Figure 3

Figure 3: Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 

Figure 3 | Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients 